2015 American Transplant Congress
Repurposing Jak/STAT Signaling Inhibition to Enhance Costimulation Blockade and Promote Transplant Acceptance
Plastic and Reconstructive Surgery, Johns Hopkins University, Baltimore.
PURPOSE: Transplant tolerance induction through conventional costimulation blockade (CoB) remains an elusive goal. Recent evidence suggests that inflammatory cytokines contribute to the activation of alloreactive…2015 American Transplant Congress
Selective Blockade of the CD28/B7/CTLA4 Pathway With Monovalent Anti-CD28 Antibodies Versus Targeting of B7 With CTLA4-Ig, in Non-Human Primate Kidney Allograft
1INSERM, UMR1064, ITUN, Nantes, France; 2Effimune SAS, Nantes, France.
B7 molecules on antigen-presenting cells interact with CD28 and CTLA4 on T lymphocytes to control TCR-mediated signals. Whereas it is highly efficient to block T…2015 American Transplant Congress
CD28 Saturation by FR104, a Non-Activating CD28 Antagonist Fab in a Non-Human Primate Cardiac Allograft Model
Background: Targeting CD28 costimulation pathway with a selective antagonist is a promising approach in tolerance induction. The extent to which novel therapeutic antibodies reach their…2015 American Transplant Congress
Selective CD28 Blockade With or Without CD40-CD154 Blockade Promotes Cardiac Allograft Protection in Non-Human Primates
1Surgery, University of Maryland School of Medicine, Baltimore, MD; 2INSERM, U643, Nants, France.
Aim: Selective targeting CD28:B7 costimulation without interfering with CTLA-4-dependent immune regulation is theoretically an attractive approach to modulate pathogenic T cell-dependent immunity. We previously reported…2015 American Transplant Congress
Costimulation Blockade and Bortezomib to Desensitize Rhesus Macaque and Prolong Renal Allograft Survival
Surgery, Emory Transplant Center, Atlanta, GA.
[Background] Preformed donor specific antibody (DSA) due to prior sensitization affects a significant population of transplant patients, portending a poorer prognosis in short- and long-term…2015 American Transplant Congress
CTLA4Ig Administered During T-Cell Priming Negates de novo Alloantibody Responses and Modulates Recall Antibody Production
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Arcadia, CA.
Background CTLA4Ig (Belatacept) is a novel anti-rejection therapy aimed at costimulatory blockade. Clinical data suggest that post-transplant alloantibody formation is also reduced in patients treated…2015 American Transplant Congress
Regulatory T Cells Expanded by Activated iNKT Cells Facilitate Migration of Donor Dendritic Cells Into the Recipient Thymus and Subsequent Establishment of Clonal Deletion
We previously reported that combination therapy using liposomal α-galactosylceramide (lipo-αGC) and anti-CD154 mAb could expand regulatory T cells (Tregs) in vivo through activation of the…2015 American Transplant Congress
Immunosuppression With Anti-CD40 mAb and Rapamycin for Islet and Kidney Co-Transplantation in Nonhuman Primates
Transplant Center, Massachusetts General Hospital, Boston, MA.
Background: For patients with end-stage renal disease secondary to type 1 diabetes mellitus, islet and kidney co-transplantation can be an ideal transplant option. However, a…2015 American Transplant Congress
Distinct Roles of CD137 and CD137L Bi-Directional Signaling in Candida albicans Infection
Invasive fungal infections by Candida albicans frequently cause mortality in immunocompromised patients, yet the cellular processes leading to this mortality remain ill-defined. Here, using genetic…2015 American Transplant Congress
Focal Segmental Glomerulosclerosis Recurrence in Renal Transplant Recipients Treated With Belatacept
Introduction: Focal segmental glomerulosclerosis (FSGS) is a cause of end-stage renal failure that frequently recurs following renal transplant, often leading to early allograft loss. A…
American Transplant Congress abstracts